Cor Vasa 2011, 53(3):158-162 | DOI: 10.33678/cor.2011.036
Bridge to heart transplantation by a combination of levosimendan and biventricular pacing in a patient with end-stage refractory heart failure
- I. interní klinika, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého, Olomouc, Česká republika
A 48-year-old man with dilated and ischemic cardiomyopathy was admitted for recurrent heart failure decompensation after all pre-vious drug therapy regimens had failed. A year before, he had biventricular pacemaker/defibrillator implantation; however, after early dislodgement of the left ventricular electrode, revision was completed with bifocal pacing (apex + right ventricular outflow tract). Orthotopic transplantation was contraindicated because of a body weight of 124 kg (limit of 100 kg). In addition to symptoms of bilateral decompensation, the patient had hypotension with blood pressure levels of 90/60 mmHg on admission, ventricular tachycardia with a rate of 140/min, and was oliguric. Following cardioversion, the ejection fraction was 19%. Intravenous furosemide had but a transient effect and the low cardiac output was progressively resulting in anuria. Despite the grim prognosis (end-stage heart failure) and contraindications (renal failure, hypotension, and ventricular tachycardia), the patient received levosimendan (a calcium senzitizer and potassium channel opener improving contractility and vasodilation). Echocardiography showed an increase in cardiac output and diuresis was restored. Due to that promising progress, a new attempt (successful) at repositioning the left ventricular electrode into the coronary sinus was made after five days, as the biventricular pacing is hemodynamically more advantageous than bifocal pacing. Echocardiography demonstrated resolved contractile synchrony and further improvement of hemodynamic parameters (rise in cardiac output, reduced size of left ventricle and atrium, reduced mitral regurgitation). The patient was discharged with compensated heart failure, and a body weight of 94 kg to have successful transplantation 12 months later. He has now been in stable condition for five years. The paper (together with detailed scans including tissue Doppler scans) documents not only the use of relatively new techniques of heart failure management capable of reversing an unfavorable course in what were formerly fatal cases but, most importantly, the fact that, in emergencies, one can go even against standard recommendations after a critical pathophysiological analysis and consideration of all the pros and cons.
Keywords: Refractory heart failure; Bridge-to-transplantation; Levosimendan; Ventricular tachycardia; Renal failure; Biventricular pacing; Bifocal pacing; Echocardiography
Published: March 1, 2011 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J 2003;4(Suppl 2):34S-38S.
Go to PubMed...
- Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol 2009;28:143-154.
Go to PubMed...
- Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007;35:2732-2739.
Go to original source...
- Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. American Heart Association Scientific Sessions November 13-16, 2005, Dallas, Texas.
- Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
Go to original source...
Go to PubMed...
- Landoni G, Mizzi A, Biondi-Zoccai G, et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 2010;76:276-286.
Go to PubMed...
- Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007;46:235-246.
Go to original source...
Go to PubMed...
- Follath F. Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Devel Ther 2009;3:73-78.
Go to original source...
Go to PubMed...
- Papadopoulos G, Baikoussis NG, Tzimas P, et al. Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction. J Cardiothorac Surg 2010;5:9.
Go to original source...
Go to PubMed...
- Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007;21:431-435.
Go to original source...
Go to PubMed...
- Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007;13:417-421.
Go to original source...
Go to PubMed...
- Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006;290:F1453-F1462.
Go to original source...
Go to PubMed...
- Flevari P, Parissis JT, Leftheriotis D, et al. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006;98:1641-1645.
Go to original source...
Go to PubMed...
- De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006;27:1908-1920.
Go to original source...
Go to PubMed...
- Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026-2033.
Go to original source...
Go to PubMed...
- Gras D, Leclercq C, Tang ASL, et al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur J Heart Fail 2002;4:311-320.
Go to original source...
Go to PubMed...
- Kuhlkamp V. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002;39:790-797.
Go to original source...
Go to PubMed...
- Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-118.
Go to original source...
- Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-1853.
Go to original source...
Go to PubMed...
- Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026-2033.
Go to original source...
Go to PubMed...
- Tushar VS, Konstantinos D, Darrel F. Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary COMPANION data with CONTAK-CD, InSync ICD, MIRACLE and MUSTIC. Int J Cardiol 2004;93:101-103.
Go to original source...
Go to PubMed...
- Pachon Mateos JC, Albornoz RN, Pachon Mateos EI, et al. Right ventricular bifocal stimulation in the treatment of dilated cardiomyopathy with heart failure. Arq Bras Cardiol 1999;73:485-498.
Go to original source...
Go to PubMed...
- Bulava A, Lukl J. Bifocal pacing - a novel cardiac resynchronization therapy? Results of bifocal pacing study and review of the current literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:303-312.
Go to original source...
Go to PubMed...